Key clinical point: Continuous or extended cycle combined oral contraceptive (COC) use was associated with a slightly elevated, but not statistically significant, risk of venous thromboembolism.
Major finding: The adjusted hazard ratio for women taking continuous/extended COCs was 1.32 (95% confidence interval, 1.07-1.74), compared with women taking noncyclic COCs, but the absolute risk difference between the two groups was low (0.27 per 1,000 persons).
Study details: A retrospective cohort study of 210,691 women with continuous/extended COC use and 522,316 women with cyclic COC use.
Disclosures: The Sentinel Initiative is funded by a contract from the Department of Health and Human Services. The authors reported no relevant conflicts of interest.
Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251
This Week's Must Reads
Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85
Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005
Adding mobile apheresis to community blood drives, Anthony D et al. AABB 2018, Poster BBC 135
Study assesses blood delivery errors, Vossoughi S et al. AABB 2018, Abstract QT4
CAR T-cell cost effectiveness in ALL, Whittington MD et al. JAMA Pediatr. 2018 Oct 8. doi: 10.1001/jamapediatrics.2018.2530
Must Reads in Thrombosis
Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30
Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919
DOACs perform well in real-world AF study, ESC CONGRESS 2018
Throly system predicts thromboprophylaxis in lymphoma patients, Leukemia and Lymphoma 2018, Dubrovnik, Croatia
VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251